Biotech

Inside the discoveries, personalities, and deals driving drug development. Sign up for The Readout newsletter to get the latest on biotech delivered to your inbox. And subscribe to STAT+ to access daily, market-moving coverage of the biotech sector — from startup funding to clinical trial readouts

In the Lab Megan Molteni

On the long road to treating Huntington’s genetic stutter, scientists return to overlooked clues

An observation made 25 years ago — and then ignored by most of the Huntington’s field — may hold the answer to a possible treatment.

Read The Story

Biotech Damian Garde and Jonathan Wosen

Detailed data on Alzheimer’s therapy from Eisai, Biogen hold up to scientific scrutiny

Biotech Allison DeAngelis

Horizon Therapeutics in acquisition talks with Amgen, Janssen, and Sanofi

Biotech Ryan Cross — The Boston Globe

mRNA startup Strand Therapeutics raises millions to test targeted cancer therapies

Biotech Allison DeAngelis

Axsome drug reduces agitation in Alzheimer’s patients, data show

All Coverage

Biotech Matthew Herper

Former Merck CEO: Democracy and the drug industry are both in danger

Biotech Adam Feuerstein

FDA approves a gene therapy for the inherited bleeding disorder hemophilia B

Biotech Adam Feuerstein

GSK to withdraw blood cancer drug from U.S. market following confirmatory study setback

Adam's Take Adam Feuerstein

Northwest Bio study of brain cancer vaccine still falls short

Pharma Adam Feuerstein

Merck to acquire Imago, bolstering pipeline for drugs targeting bone marrow diseases

Biotech Jonathan Wosen

mRNA revolutionized the race for a Covid-19 vaccine. Could cancer be next?

Biotech Jonathan Wosen

Biosplice, once the most valuable biotech startup, sees a pair of osteoarthritis trials fail

Biotech Jonathan Wosen

mRNA drugs with a built-in ‘copy machine’ could lead to safer, more effective therapies

Biotech Jason Mast

Editas, facing another setback, halts development on first clinical CRISPR program

Biotech Jonathan Wosen

Vertex revolutionized cystic fibrosis treatment. Its executives say that’s just the start

Biotech Adam Feuerstein, Jason Mast and Damian Garde

‘We were right all along:’ For Japanese drugmaker Eisai, success against Alzheimer’s has been a long time coming

First Opinion Anup Srivastava, Rong Zhao and Ge Bai

The conundrum of biopharma investing: low rewards and high risks — but a big social benefit

Biotech Olivia Goldhill

The scientist behind Pfizer’s Covid vaccine says a flu pandemic is only a matter of time

Biotech Catherine Carlock — Boston Globe

Cooling demand for new lab space in Boston could be good news for biotech companies

Biotech Allison DeAngelis

Thrive founders launch new blood testing startup to spot when cancer returns

Biotech Jonathan Wosen

Covid-19 vaccines were a success, but mRNA still has a delivery problem. Two startups have an unorthodox solution

Health Eleanor Cummins

After decades of setbacks, scientists make strides toward the holy grail of male birth control

Biotech Jason Mast

‘If this works, it changes everything’: Altos Labs founders lay out plan to reverse disease

Biotech Megan Molteni

Perfection is too high a bar for CRISPR treatments, says STAT Biomedical Innovation Award winner David Liu

In the Lab Jonathan Wosen

5 looming questions about the exodus of young life scientists from academia

Biotech Adam Feuerstein

Immunogen wins FDA approval for targeted medicine to treat advanced ovarian cancer

Biotech Adam Feuerstein

Despite higher dose, Stoke Therapeutics drug not active enough against childhood epilepsy

Health Matthew Herper

Moderna data suggest new Covid booster is more effective against Omicron variants

Biotech Jonathan Wosen

Biotech

On the long road to treating Huntington’s genetic stutter, scientists return to overlooked clues

Detailed data on Alzheimer’s therapy from Eisai, Biogen hold up to scientific scrutiny

Horizon Therapeutics in acquisition talks with Amgen, Janssen, and Sanofi

mRNA startup Strand Therapeutics raises millions to test targeted cancer therapies

Axsome drug reduces agitation in Alzheimer’s patients, data show

All Coverage

Former Merck CEO: Democracy and the drug industry are both in danger

FDA approves a gene therapy for the inherited bleeding disorder hemophilia B

GSK to withdraw blood cancer drug from U.S. market following confirmatory study setback

Northwest Bio study of brain cancer vaccine still falls short

Merck to acquire Imago, bolstering pipeline for drugs targeting bone marrow diseases

mRNA revolutionized the race for a Covid-19 vaccine. Could cancer be next?

Biosplice, once the most valuable biotech startup, sees a pair of osteoarthritis trials fail

mRNA drugs with a built-in ‘copy machine’ could lead to safer, more effective therapies

Editas, facing another setback, halts development on first clinical CRISPR program

Vertex revolutionized cystic fibrosis treatment. Its executives say that’s just the start

‘We were right all along:’ For Japanese drugmaker Eisai, success against Alzheimer’s has been a long time coming

The conundrum of biopharma investing: low rewards and high risks — but a big social benefit

The scientist behind Pfizer’s Covid vaccine says a flu pandemic is only a matter of time

Cooling demand for new lab space in Boston could be good news for biotech companies

Thrive founders launch new blood testing startup to spot when cancer returns

Covid-19 vaccines were a success, but mRNA still has a delivery problem. Two startups have an unorthodox solution

After decades of setbacks, scientists make strides toward the holy grail of male birth control

‘If this works, it changes everything’: Altos Labs founders lay out plan to reverse disease

Perfection is too high a bar for CRISPR treatments, says STAT Biomedical Innovation Award winner David Liu

5 looming questions about the exodus of young life scientists from academia

Immunogen wins FDA approval for targeted medicine to treat advanced ovarian cancer

Despite higher dose, Stoke Therapeutics drug not active enough against childhood epilepsy

Moderna data suggest new Covid booster is more effective against Omicron variants

After blazing trails in RNA-targeted drugs, Ionis jumps into gene editing

You've been selected! STAT+ for less than $2/day

Subscribe to STAT+ for less than $2 per day